Enrolling Clinical Research Studies

Chronic Pancreatitis

Clostridium Difficile Infection

Crohn's Disease

Eosinophilic Esophagitis

Gastroparesis

Ulcerative Colitis

Clostridium Difficile Infection
Is Another Clostridium Difficile Infection Getting in the Way of Your Life

Is Another Clostridium Difficile Infection Getting in the Way of Your Life

Why is the ECOSPOR III study Important?

The leading risk factor for Clostridium difficile infection (CDI) is a prior history of taking antibiotics.  Exposure to antibiotics can harm the good bacteria in the gut that make up our microbiome.  These beneficial bacteria protect us from harmful invaders, like C. difficile, which can cause diarrhea.  Although CDI treatment is available, many patients continue to have recurrent infections because their microbiome doesn't recover.

To qualify for this study, a person must:

  • Be 18 years of age or older
  • Have a documented history of at least 3 episodes of CDI in the last 9 months, including the current episode 

All study-related visits, tests, and medication will be provided to participants at no cost.  Reimbursement for time and travel may be provided.

 

» Study Details | Apply for the Study

Are You Fighting C-Diff?

Are You Fighting C-Diff?

The PRISM 3 clinical research study is for patients who have had a recurrence of Clostridium difficile infection (CDI or C. diff).  The study will evaluate the safety and effectiveness of the study drug to prevent recurrence of CDI compared against placebo.

» Study Details | Apply for the Study

Crohn's Disease
Crohn's Disease but currently have side effects or symptoms?

Crohn's Disease but currently have side effects or symptoms?

If you have Crohn's consider taking part in the Etro Study.

  • Have you been diagnosed with Crohn's?
  • Have received or are receiving treatment for Crohn's, but had or currently have side effects or symptoms?
  • Do not have a ileostomy or colostomy?

WHY PARTICIPATE IN A CLINCIAL TRIAL?

You may get expert medical care from leading specialists and nurses throughout the study

You remain in control of your level of participation

You contribute to scientific understanding of Crohn's

» Study Details | Apply for the Study

Eosinophilic Esophagitis (EOE)
Is Eosinophilic Esophagitis (EoE) Affecting Your Meals?

Is Eosinophilic Esophagitis (EoE) Affecting Your Meals?

Does the thought of eating certain foods make you anxious or uneasy?

Do they trigger swallowing difficulties, vomiting, or abdominal pain?

Then you may be able to take part in a new clinical research study. 

» Study Details | Apply for the Study

Gastroparesis
Have you been diagnosed with either idiopathic or diabetic gastroparesis?

Have you been diagnosed with either idiopathic or diabetic gastroparesis?

You might qualify for a clinical study for a new medication for nausea and the symptoms of gastropareses.

Qualified participants will receive study-related care and study medication at no charge as well as receive reimbursement for time and participation.

A high percentage of gastroparesis patients have difficulty with a variety of symptoms from abdominal pain to nausea and vomiting. 

Researchers in the United States are looking for up to 150 adults diagnosed with idiopathic or diabetic gastroparesis who

 

  • are between 18 and 70 years of age
  • experience significant symptoms of gastroparesis such as nausea 

 

» Study Details | Apply for the Study

Chronic Pancreatitis
Chronic Pancreatitis Research Study

Chronic Pancreatitis Research Study

Have you been clinically diagnosed with CHRONIC PANCREATITIS?

Do you have ABDOMINAL PAIN associated with your disease?

You may be eligible to participate in a clinical research study, being conducted in your local area, evaluating the effects of an investigational drug on pain related to chronic pancreatitis. 

» Study Details | Apply for the Study

Ulcerative Colitis
UC GOES EVERYWHERE WITH YOU

UC GOES EVERYWHERE WITH YOU

What is the study about?

FIGARO 302 is a clinical research study designed to explore an investigational drug-SHP647-for participants with moderate-to-severe ulcerative colitis (UC) who have responded inadequately to conventional treatment. 

 

» Study Details | Apply for the Study

Powered By RealTime-CTMS Clinical Trial Management System